Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut [Yahoo! Finance]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
The figure was wider than the Zacks Consensus Estimate of a loss of 20 cents per share. Consolidated revenues totaled $708.7 million, up 12.8% on a reported basis and 13% on a core revenue basis. The figure missed the Zacks Consensus Estimate by 1.2%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar Following the announcement, EXAS' shares plunged nearly 30% in the after-hours trading yesterday. Screening revenues, including laboratory service revenues from Cologuard and PreventionGenetics, totaled $544.9 million. The figure increased 15% year over year, due to a rise in the number of completed Cologuard tests. Precision Oncology revenues, including laboratory service revenues from global Oncotype products and therapy selection products, were $163.8 million, up 5% year over year and on a core basis. This upside was propelled by Oncotype DX, which expanded 28% internationally. The company did not recognize any revenues from COVID testing in the third q
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) [Seeking Alpha]Seeking Alpha
- EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community [Yahoo! Finance]Yahoo! Finance
EXAS
Earnings
- 11/5/24 - Miss
EXAS
Sec Filings
- 11/13/24 - Form SC
- 11/13/24 - Form 4
- 11/8/24 - Form SC
- EXAS's page on the SEC website